Xiao-Jun Chen1, Fan Yang1, Zhen-Qiu Chen2,3, Min-Cong He1, Guo-Ju Hong1, Jun-Yuan Huang4, Ying-Chun Zhou4, Yi-Xian Qin5, Qiu-Shi Wei6,7, Wei He8,9. 1. First Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou, People's Republic of China. 2. Hip Preserving Ward, No.3 Orthopaedic Region, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, No.16, Jichang Road, Baiyun District, Guangzhou, 510407, People's Republic of China. 3. Institute of Hip Joint, Guangzhou University of Chinese Medicine, Guangzhou, People's Republic of China. 4. Medical Laboratory Department, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, People's Republic of China. 5. Department of Biomedical Engineering, Stony Brook University, Stony Brook, NY, USA. 6. Hip Preserving Ward, No.3 Orthopaedic Region, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, No.16, Jichang Road, Baiyun District, Guangzhou, 510407, People's Republic of China. weiqshi@126.com. 7. Institute of Hip Joint, Guangzhou University of Chinese Medicine, Guangzhou, People's Republic of China. weiqshi@126.com. 8. Hip Preserving Ward, No.3 Orthopaedic Region, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, No.16, Jichang Road, Baiyun District, Guangzhou, 510407, People's Republic of China. hw13802516062@163.com. 9. Institute of Hip Joint, Guangzhou University of Chinese Medicine, Guangzhou, People's Republic of China. hw13802516062@163.com.
Abstract
PURPOSE: Sclerostin is an osteocyte-derived protein that has a potent inhibitory effect on osteoblast activity. The osteocyte apoptosis induced by various causes of osteonecrosis of the femoral head (ONFH) plays a key role in the promotion of femoral head collapse. But the effect of altering sclerostin level on the collapse of ONFH has not been studied. Our aim was to assess the role of sclerostin level in the collapse of ONFH. METHODS: Between May 2016 and November 2016, 236 subjects were enrolled in the present study. The patients were classified according to the Association Research Circulation Osseous (ARCO) classification. The clinical bone histomorphology, the expression position, and level of sclerostin as well as the plasma sclerostin level were evaluated. RESULTS: The sclerostin level was significantly lower in the non-traumatic ONFH group than those in the healthy control group (P = 0.002). The sclerostin level was negatively associated with ARCO stages (r = - 0.239, P = 0.009) and significantly lower in the postcollapse group (P = 0.025). CONCLUSIONS: The reduced expression of sclerostin may play a key role in the collapse process of ONFH and be predictive of the disease progression of ONFH.
PURPOSE:Sclerostin is an osteocyte-derived protein that has a potent inhibitory effect on osteoblast activity. The osteocyte apoptosis induced by various causes of osteonecrosis of the femoral head (ONFH) plays a key role in the promotion of femoral head collapse. But the effect of altering sclerostin level on the collapse of ONFH has not been studied. Our aim was to assess the role of sclerostin level in the collapse of ONFH. METHODS: Between May 2016 and November 2016, 236 subjects were enrolled in the present study. The patients were classified according to the Association Research Circulation Osseous (ARCO) classification. The clinical bone histomorphology, the expression position, and level of sclerostin as well as the plasma sclerostin level were evaluated. RESULTS: The sclerostin level was significantly lower in the non-traumatic ONFH group than those in the healthy control group (P = 0.002). The sclerostin level was negatively associated with ARCO stages (r = - 0.239, P = 0.009) and significantly lower in the postcollapse group (P = 0.025). CONCLUSIONS: The reduced expression of sclerostin may play a key role in the collapse process of ONFH and be predictive of the disease progression of ONFH.
Entities:
Keywords:
Biomarker; Collapse; Osteonecrosis of the femoral head; Sclerostin
Authors: D B Maurel; C Jaffre; G Y Rochefort; P C Aveline; N Boisseau; R Uzbekov; D Gosset; C Pichon; N L Fazzalari; S Pallu; C L Benhamou Journal: Bone Date: 2011-06-13 Impact factor: 4.398
Authors: Martina Wengenroth; Gergely Vasvari; Philipp A Federspil; Johanna Mair; Peter Schneider; Christoph Stippich Journal: Radiology Date: 2009-10 Impact factor: 11.105
Authors: Michael A Mont; Hytham S Salem; Nicolas S Piuzzi; Stuart B Goodman; Lynne C Jones Journal: J Bone Joint Surg Am Date: 2020-06-17 Impact factor: 6.558
Authors: Elias S Vasiliadis; Dimitrios-Stergios Evangelopoulos; Angelos Kaspiris; Ioannis S Benetos; Christos Vlachos; Spyros G Pneumaticos Journal: J Clin Med Date: 2022-02-02 Impact factor: 4.241